


# Colistimethate sodium



**Colistimethate sodium** is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including *Enterobacter aerogenes*, *Escherichia coli*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*.

**Indication:** Used in the treatment of acute or chronic infections due to sensitive strains of Gram-negative pathogens, especially in patients with limited treatment options.

**Application:** Administered systemically as intramuscular injections and intravenous injections or infusions. Colistimethate sodium can also be administered by inhalation or mixed with bone cement, as well as used in ophthalmic formulations.

<b>Product grades</b>	Sterile, micronized	Sterile, non-micronized	Non-sterile, non-micronized
<b>Compliance</b>	Ph. Eur. USP		
<b>Manufacturing site</b>	Xellia Pharmaceuticals ApS, Copenhagen, Denmark		
<b>Release site</b>	Xellia Pharmaceuticals ApS, Copenhagen, Denmark		
<b>Site registered</b>	EU GMP issued by Danish Medicines Agency US FDA Other health authorities		
<b>Regulatory documentation</b>	EU Drug Master File (DMF)/Certificate of Suitability (CEP) US Drug Master File (DMF) Letter of Access (LoA)		
<b>Packaging sizes</b>	<b>Sterile, micronized</b> 10 BOU*	<b>Sterile, non-micronized</b> 15 BOU* 65 BOU*	<b>Non-sterile, non-micronized</b> 15 BOU* 65 BOU*
<b>Packaging material</b>	Primary: Aluminium containers with polyethylene insert and polypropylene lid Secondary: Polystyrene		
<b>Shelf-life</b>	5 years		
<b>Storage conditions</b>	Below 25°C (77°F)		

\*Billion Of Units